Table 3.
Associations Between Biomarkers and Ischemic Stroke Using Conditional Logistic Regression With the Imputed Data Set, Restricted to Matched Cases and Controls Whose Viral Load Was <400 Copies/mL (n=89)
| Biomarker | OR (95% CI) | P Value | Model 1: Adjusted for Age and Sex, AOR (95% CI) | P Value | Model 2: Adjusted for ASCVD Score, AOR (95% CI) | P Value | Model 3: Adjusted for VACS Score, AOR (95% CI) | P Value |
|---|---|---|---|---|---|---|---|---|
| Log10 viral load | 2.79 (0.65–11.9) | .17 | 3.56 (0.62–20.4) | .16 | 2.74 (0.36–21.2) | .33 | 1.34 (0.24–7.38) | .74 |
| Log10 peak viral load | 1.10 (0.72–1.68) | .66 | 1.18 (0.75–1.86) | .48 | 0.90 (0.51–1.61) | .73 | 1.15 (0.71–1.86) | .56 |
| CD4 count, per 100 cells | 0.98 (0.85–1.14) | .83 | 0.97 (0.82–1.13) | .66 | 0.98 (0.81–1.18) | .83 | 1.12 (0.93–1.33) | .23 |
| Nadir CD4 count, per 100 cells | 0.74 (0.50–1.10) | .14 | 0.77 (0.51–1.15) | .21 | 0.78 (0.49–1.25) | .30 | 0.83 (0.54–1.29) | .41 |
| Log2 angiopoietin-1 | 0.90 (0.64–1.27) | .55 | 0.93 (0.64–1.36) | .72 | 0.87 (0.56 –1.36) | .54 | 1.05 (0.72–1.54) | .80 |
| Log2 angiopoietin-2 | 1.33 (0.85–2.06) | .21 | 1.46 (0.87–2.46) | .15 | 1.72 (0.96–3.10) | .07 | 0.95 (0.57–1.60) | .86 |
| Log2 C-reactive protein | 1.13 (0.92–1.39) | .25 | 1.18 (0.92–1.52) | .20 | 1.15 (0.89–1.48) | .28 | 1.08 (0.85–1.38) | .51 |
| Log2 interleukin-6 | 1.16 (0.81–1.67) | .41 | 1.15 (0.77–1.72) | .49 | 1.31 (0.79–2.18) | .30 | 0.96 (0.63–1.48) | .86 |
| Log2 plasma activation inhibitor–1 | 0.73 (0.46–1.15) | .17 | 0.81 (0.48–1.37) | .44 | 0.70 (0.37–1.34) | .29 | 0.92 (0.52–1.63) | .79 |
| Log2 P-selectin | 1.19 (0.58–2.46) | .64 | 0.97 (0.43–2.19) | .94 | 0.72 (0.28–1.88) | .50 | 1.06 (0.48–2.34) | .89 |
| Log2 soluble ICAM-1 | 1.30 (0.58–2.90) | .52 | 1.19 (0.50–2.88) | .69 | 1.48 (0.53–4.15) | .46 | 0.98 (0.36–2.64) | .97 |
| Log2 soluble VCAM-1 | 0.98 (0.51–1.91) | .96 | 1.00 (0.49–2.07) | .99 | 1.24 (0.54–2.84) | .61 | 0.41 (0.15–1.11) | .08 |
| Log2 serum amyloid A | 1.09 (0.86–1.40) | .47 | 1.15 (0.86–1.54) | .36 | 1.15 (0.86–1.55) | .34 | 1.05 (0.80–1.38) | .71 |
| Log2 soluble CD14 | 1.35 (0.52–3.49) | .54 | 1.89 (0.61–5.88) | .27 | 1.84 (0.51–6.65) | .35 | 0.60 (0.18–2.00) | .40 |
| Log2 apolipoprotein 1 | 0.77 (0.27–2.17) | .62 | 0.73 (0.23–2.35) | .60 | 0.93 (0.24–3.57) | .92 | 0.58 (0.16–2.02) | .39 |
| Log2 ADAMTS-13 | 1.29 (0.55–3.02) | .56 | 1.41 (0.55–3.62) | .47 | 2.16 (0.63–7.36) | .22 | 1.62 (0.60–4.38) | .35 |
| Log2 von Willebrand factor | 1.61 (0.99–2.62) | .06 | 1.60 (0.90–2.82) | .11 | 1.64 (0.88–3.05) | .12 | 1.59 (0.93–2.74) | .09 |
Abbreviations: AOR, adjusted odds ratio; ASCVD, Atherosclerotic Cardiovascular Disease score; CD4, cluster of differentiation 4; OR, odds ratio; VACS, Veterans Aging Cohort Study.